Workiva Inc. stock is a Buy as strong revenue growth, margin gains, and SaaS demand fuel positive earnings. Click here for ...
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback